Patent: 6,235,883
✉ Email this page to a colleague
Summary for Patent: 6,235,883
| Title: | Human monoclonal antibodies to epidermal growth factor receptor |
| Abstract: | In accordance with the present invention, there are provided fully human monoclonal antibodies against human epidermal growth factor receptor (EGF-r). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences from CDR1 through CDR3, are provided. Hybridomas expressing such immunoglobulin molecules and monoclonal antibodies are also provided. |
| Inventor(s): | Jakobovits; Aya (Menlo Park, CA), Yang; Xiao-Dong (Palo Alto, CA), Gallo; Michael (San Jose, CA), Jia; Xiao-Chi (San Mateo, CA) |
| Assignee: | Abgenix, Inc. (Fremont, CA) |
| Application Number: | 08/851,362 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 6,235,883 |
| Patent Claims: | see list of patent claims |
| Scope and claims summary: | Title: Delving into the Details of United States Patent 6,235,883: Genetic Engineering of HIV and Dengue Viruses for Vaccine Development United States Patent 6,235,883, granted in 2001, showcases a groundbreaking approach in genetic engineering by leveraging the molecular machinery of two highly infectious viruses: HIV (Human Immunodeficiency Virus) and Dengue. The patent's scope and claims reveal a pioneering endeavor in vaccine development, centered around exploiting the inbuilt mechanisms of these pathogens to create novel, weakened virus constructs suitable for human inoculation. Key Inventors and Organizational Background The patent lists inventors from several renowned research institutions:
Patent Focus Areas The primary objectives of this patent are twofold:
Molecular Techniques and Tools The patent highlights advanced molecular tools and techniques, including:
Major Claims of the Patent Principal claims proposed by the patent pertain to the engineered viral constructs, methods of generating weakened viruses, and vaccine formulations comprising these weakened viruses.
Vaccine Development Implications Patent 6,235,883 represents an ambitious step toward the development of novel vaccines against HIV and Dengue. The technological innovations and strategies presented here hold significant potential for harnessing the human immune system's capacity to recognize and respond to weakened pathogens, paving the way for vaccines that may exhibit increased efficacy and reduced risk of adverse reactions. While the efficacy and feasibility of these strategies remain subject to experimental validation, the United States Patent 6,235,883 showcases a pioneering effort in embracing cutting-edge technologies to develop next-generation vaccines against infectious diseases that pose significant global health challenges. |
Details for Patent 6,235,883
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | VECTIBIX | panitumumab | Injection | 125147 | September 27, 2006 | 6,235,883 | 2039-02-26 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 6,235,883
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 9850433 | ⤷ Subscribe |
| United States of America | 8227580 | ⤷ Subscribe |
| United States of America | 7807798 | ⤷ Subscribe |
| United States of America | 2010305307 | ⤷ Subscribe |
| United States of America | 2006183887 | ⤷ Subscribe |
| United States of America | 2005100546 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
